



AMENDMENTS TO THE CLAIMS

1.(original) A compound of formula (I)
N-Ac-Sar-Gly-AA³-AA⁴-AA⁵-AA⁶-AA⁷-Arg-Pro-AA¹⁰
(I),

or a pharmaceutically acceptable salt, ester, prodrug, or solvate thereof, wherein

AA³ is selected from the group consisting of

- (1) glutaminyl,
- (2) phenylalanyl,
- (3) valyl, and
- (4) asparaginyl;

AA⁴ is selected from the group consisting of

- (1) D-isoleucyl,
- (2) isoleucyl,
- (3) D-leucyl, and
- (4) D-alloisoleucyl;

AA⁵ is selected from the group consisting of

- (1) seryl,
- (2) methionyl,
- (3) allothreonyl,
- (4) threonyl, and
- (5) tyrosyl;

AA⁶ is selected from the group consisting of

- (1) norvalyl,
- (2) seryl,
- (3) tryptophyl,
- (4) glutaminyl, and
- (5) prolyl;

AA⁷ is selected from the group consisting of

- (1) isoleucyl,
- (2) D-isoleucyl,
- (3) lysyl(acetyl), and
- (4) prolyl; and

AA¹⁰ is selected from the group consisting of

- (1) D-alanylamine,
- (2) ethylamine, and
- (3) isopropylamine;

with the proviso that one of AA⁴ and AA⁷ is a D-amino acid.

2. (original) A compound according to Claim 1 wherein AA⁴ is D-Ile.

3. (original) A compound according to Claim 2 selected from the group consisting of
 N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
 N-Ac-Sar-Gly-Phe-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
 N-Ac-Sar-Gly-Val-D-Ile-alloThr-Nva-Ile-Arg-ProNHCH₂CH₃,
 5 N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-D-Ile-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-D-Ile-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Asn-D-Ile-Thr-Nva-Lys(Ac)-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Val-D-Ile-alloThr-Ser-Ile-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Gln-D-Ile-alloThr-Nva-Ile-Arg-ProNHCH₂CH₃,
 10 N-Ac-Sar-Gly-Val-D-Ile-alloThr-Nva-Pro-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-D-Ile-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Val-D-Ile-Met-Nva-Ile-Arg-Pro-D-AlaNH₂, and
 N-Ac-Sar-Gly-Val-D-Ile-alloThr-Pro-Ile-Arg-ProNHCH₂CH₃.

4. (original) A compound according to Claim 1 wherein AA⁴ is D-Leu.

A₁ 5. (original) A compound according to Claim 4 selected from the group consisting of
 N-Ac-Sar-Gly-Asn-D-Leu-Ser-Nva-Ile-Arg-ProNHCH₂CH₃, and
 N-Ac-Sar-Gly-Asn-D-Leu-Thr-Ser-Ile-Arg-ProNHCH₂CH₃.

6. (original) A compound according to Claim 1 wherein AA⁴ is D-alloIle.

7. (original) A compound according to Claim 6 selected from the group consisting of
 N-Ac-Sar-Gly-Val-D-alloIle-Ser-Thr-Ile-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Gln-D-alloIle-Tyr-Nva-D-Ile-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Gln-D-alloIle-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,
 5 N-Ac-Sar-Gly-Val-D-alloIle-Thr-Trp-Ile-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH(CH₃)₂,
 N-Ac-Sar-Gly-Val-D-alloIle-Thr-Trp-D-Ile-Arg-ProNHCH₂CH₃,
 N-Ac-Sar-Gly-Val-D-alloIle-alloThr-Gln-Ile-Arg-ProNHCH₂CH₃, and
 N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-Pro-D-AlaNH₂.

- 10 8. (currently amended) A pharmaceutical composition comprising a compound of
 Claim 1, or a ~~pharmaceutically~~ pharmaceutically acceptable salt, ester, prodrug, or solvate
 thereof, and a pharmaceutically acceptable carrier.

9. (withdrawn)

10. (currently amended) A composition for the treatment of a disease selected from
 cancer, arthritis, psoriasis, angiogenesis of the eye associated with infection or surgical
 intervention, macular degeneration and diabetic retinopathy comprising a peptide as defined
 in Claim 1, or a ~~pharmaceutically~~ pharmaceutically acceptable salt, ester, prodrug, or solvate

5 thereof, in combination with a pharmaceutically acceptable carrier.

11. (withdrawn)

12. (original) A compound selected from the group consisting of

N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,

N-Ac-Sar-Gly-Phe-D-Ile-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,

N-Ac-Sar-Gln-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

5 N-Ac-Sar-Gly-Val-D-Ile-alloThr-Nva-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Nva-D-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Asn-D-Leu-Ser-Nva-Ile-Arg-ProNHCH₂CH₃,

N-(6-Me-Nicotinyl)-Sar-Gly-Val-D-Ile-Thr-Nva-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-Ile-Thr-Nva-D-Ile-Arg-ProNHCH₂CH₃,

10 N-Ac-Sar-Gly-Val-D-alloIle-Ser-Thr-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Gln-D-Ile-Thr-Nva-D-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Asn-D-Ile-Thr-Nva-Lys(Ac)-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Gln-D-alloIle-Tyr-Nva-D-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Gln-D-alloIle-Thr-Nva-Ile-Arg-Pro-D-AlaNH₂,

15 N-Ac-Sar-Gly-Asn-D-Leu-Thr-Ser-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-Ile-alloThr-Ser-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Gln-D-Ile-alloThr-Nva-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-Ile-alloThr-Nva-Pro-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Trp-Ile-Arg-ProNHCH₂CH₃,

20 N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-ProNHCH(CH₃)₂,

N-Ac-Sar-Gly-Val-D-Ile-Thr-Gln-D-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Trp-D-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-alloIle-Thr-Nva-Ile-Arg-D-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-Ile-Met-Nva-Ile-Arg-Pro-D-AlaNH₂,

25 N-Ac-Sar-Gly-Val-D-Ile-alloThr-Pro-Ile-Arg-ProNHCH₂CH₃,

N-Ac-Sar-Gly-Val-D-alloIle-alloThr-Gln-Ile-Arg-ProNHCH₂CH₃, and

N-Ac-Sar-Gly-Val-D-alloIle-Ser-Ser-Ile-Arg-Pro-D-AlaNH₂.
